Cellectis S.a. · EURONEXT:ALCLS
Cellectis — Investor Day (October 2025)
65 slides from Cellectis's investor day presentation, Oct 17, 2025
Slide 1: R&D Day BALLI-01 Phase 1 & Phase 2 Strategy
Exhibit 99.2 R&D Day BALLI-01 Phase 1 & Phase 2 Strategy DRAFT
Slide 2: Forward-Looking Statements
Forward-Looking Statements Forward Looking Statement This presentation contains “forward-looking” statements within These forward-looking statements are made in light of the meaning of applicable securities laws, including the Private information currently available to us and are subject to Securiti
Slide 3: Lasmecabtagene Timgedleucel (Lasme-cel, UCART22)
Lasmecabtagene Timgedleucel or Lasme-cel (UCART22) Lasme-cel could be a game changer in refractory or relapsed B-ALL Lasme-cel is not FDA approved P3
Slide 4: Today's Reveal
Today’s Reveal 1. The BALLI-01 Study for Patients with r/r B-ALL • Phase 1 Update → Lessons Learned • Phase 2 Design → Path to BLA and Market Panel Discussion with Oncology Experts 2. Lasme-cel Market Opportunity • Patient Need & Addressable Market • Where We Create Value 4. Building Tomorrow’s Cell
Slide 5: B-ALL: An Unmet Medical Need
B-ALL: An Unmet Medical Need ALL: an Unmet Medical Need B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA • 1L treated population: ~9,200 Patients (US, EU4, UK)* High relapse in adults HURDLES WITH EXISTING TREATMENTS • Chemotherapies: Lead to high relapse rate in adults • ADCs have a limited effect: Low antigen
Slide 6: Why an Allogeneic CD22 CAR-T Cell Product for r/r B-ALL?
Why an Allogeneic CD22 CAR-T cell Product for r/r B-ALL? Why an Allogeneic CD22 CAR-T cell product for r/r B-ALL? Allogeneic CAR-T Starts with Healthy-donor T Cells Healthier and less exhausted than autologous cells from heavily pretreated patients Off-the-Shelf is designed for “Speed” – in B-ALL Ev
Slide 7: Fully Integrated Manufacturing
Fully Integrated Manufacturing Fully Integrated Manufacturing Paris, France Raleigh, NC CMC Development, UCART – Clinical & Intended Starting Materials Commercial Ready Site Allogeneic CAR-T 14,000 sq ft. facility 82,000 sq ft. facility ✓ Process & analytical development ✓ UCART GMP manufacturing ✓
Slide 8: Lasme-cel as Bridge to Transplant Strategy
Lasme-cel as Bridge to Transplant Strategy Lasme-cel as Bridge to Transplant Strategy HSCT as the Gold Standard For r/r B-ALL THE GOAL Achieve a Path to a Potentially Curative HSCT ➢ Secure a remission window ➢ Make patient eligible for an HSCT ➢ Clear path to long-term remission ➢ Manageable safety
Slide 9: BALLI-01 Phase 1 Data Review & Design of Pivotal Phase 2
R&D Day BALLI-01 Phase 1 Data Review & Design of Pivotal Phase 2 DRAFT
Slide 10: Eti-cel (UCART20x22): High Response Rates in R/R NHL
Eti-cel (UCART20x22): High Response Rates in R/R NHL Response rate (%) [n=7] 100 90 80 70 60 4/7 CR at 50 86% Current 40 Dose 57% 30 Level 20 10 0 ORR CR Update on Program at the End of the Year 2025 ORR: overall response rate; CR: complete response ; r/r NHL: Relapsed or refractory non-Hodgkin lymp
Slide 11: B-ALL: Chemo and Targeted Therapies Lead, Transplant Is the Cure
B-ALL: Chemo and Targeted Therapies Lead, Transplant Is the Cure ALL Treatment Paradigm 1 Induction: Chemo (± TKI ) Frontline All patients Consolidation: Chemo ± TKI (MRD-) Blincyto (MRD+) Chemo Auto CD19 nd 2 Line (R/R) Blincyto Besponsa (± TKI) CAR-T rd Auto CD19 Other (i.e., Chemo, Clinical 3 Lin
Slide 12: Poor Response Rates after Targeted Therapy Failure
1 Poor Response Rates after Targeted Therapy Failure 2 After targeted therapy failure, salvage chemo yields low ODD and MRD : High unmet need in Post Ino failure Post CAR-T failure Post Blina failure heavily pretreated patients ORR <20% ORR <10-15% ORR <10% MRD-ve <10% MRD-ve <5-10% MRD-ve <5% P12 1
Slide 13: Key Questions Being Addressed in BALLI-01 Trial
Key Questions Being Addressed in BALLI-01 Trial Is Alemtuzumab needed to Is Cellectis’ manufactured optimize response? product superior? Which endpoint best What is the optimal dose? reflects benefit? P13
Slide 14: BALLI-01 Study Design
BALLI-01 Study Design Is our internal manufacturing superior? Process 1 vs Process 2 5 DL1=1×10 cells/kg 6 DL2= 1×10 cells/kg 6 DL2i= 2.5×10 cells/kg 6 DL 3 DL 3 DL3= 5×10 cells/kg DL 2i DL 2i Study What is the design optimal dose? DL 2 DL 2 DL 2 DL 1 FC vs FCA Is alemtuzumab necessary? P14 DL1: Dos
Slide 15: Cellectis Manufactured Product (P2) Is Superior to CDMO Product (P1)
Cellectis Manufactured Product (P2) Is Superior to CDMO Product (P1) Overall Response Rate (%) 80 70 68 60 Higher 32 50 response 40 28 30 rates in 6 20 36 P2 cohort 22 10 0 P1 (n=18 P2 (n=22) CR/CRi MLFS P15 Percentage (%)
Slide 16: BALLI-01 Phase 1 Data
R&D Day BALLI-01 Phase 1 Data DRAFT
Slide 17: BALLI-01 Study Design
BALLI-01 Study Design Process 1 vs Process 2 5 DL1=1×10 cells/kg 6 DL2= 1×10 cells/kg 6 DL2i= 2.5×10 cells/kg 6 DL 3 DL 3 DL3= 5×10 cells/kg DL 2i DL 2i Study design DL 2 DL 2 DL 2 DL 1 FC vs FCA P17 DL1: Dose Level 1; DL2: Dose Level 2; DL2i: Intermediate Dose Level 2; DL3: Dose Level 3; FC: Fludar
Slide 18: BALLI-01 Key Inclusion Criteria
BALLI-01 Key Inclusion Criteria All patients Key Inclusion Key Outcomes Exploratory transplant Objectives • Age 15-70 years, • Safety ineligible at adequate organ • Investigator • UCART22 function study entry expansion assessed • ECOG PS ≤1 response • Trafficking, persistence • B-ALL blast CD22 • RP
Slide 19: Demographic and Baseline Characteristics
BALLI 01 | Demographic and Baseline Characteristics All Subjects DL3 P2 (n=12) Age ≤ 50 (n=9) Total (n=40) Age (yrs), median (range) 27 (16-66) 23 (16-45) 27 (16-68) Sex, n (%) Male 5 (41.7) 3 (33.3) 22 (55) Female 7 (58.3) 6 (66.7) 18 (45) ECOG PS, n (%) 0 5 (41.7) 4 (44.4) 14 (35) 1 6 (50) 4 (44.4
Slide 20: Heavily Pretreated Population: Median 4-5 Prior Lines of Therapy
Heavily Pretreated Population: Median 4-5 Prior Lines of Therapy Significant prior treatment with targeted therapies 80% 55% 50% Previously Previously Previously treated treated treated P20
Slide 21: High Response Rates in P2 Cohort
High Response Rates in P2 Cohort Recommended Phase 2 Dose: DL3 Target Phase 2 population: ▪ DL3 ≤ 50 years P21
Slide 22: High Response Rates in P2 Cohort
High Response Rates in P2 Cohort In Target Phase 2 population 80% who achieved CR/CRi were also MRD-ve P22
Slide 23: Deep Responses in P2 Cohort
Deep Responses in P2 Cohort Responder MRD-negative Status (%) 100 CR/CRI ORR 90 80 80 77 80 75 73 High Rates 70 70 60 of MRD 60 50 Negativity 50 40 in Both 30 Cohorts 20 10 0 P1 P2 P2 DL3 Target Phase 2 Population n=22 n=12 n=18 n=9 P23 CRi: Complete Remission with incomplete hematologic recovery Pe
Slide 24: Swimmer Plot – Target Phase 2 Population
Swimmer Plot – Target Phase 2 Population Prior (HSCT+Blin+Ino+CAR-T) 9 T T Prior (Blin) 8 T T 7 Prior (Blin+Ino+CAR-T) T T 6 T Prior (Blin) T 5 Prior (Blin+Ino+CAR-T) T T HSCT Hematopoietic Stem Cell Transplant Blin Blinatumomab Prior (HSCT+Blin+Ino+CAR-T) 4 Ino Inotuzumab CAR-T CAR-T Cell Therapy 3
Slide 25: Improved Survival in Patients Who Responded
Improved Survival in Patients Who Responded Overall Survival over 12 months by Response (P2) Median Overall Survival in Subjects who Achieve MRD- negative CR/CRi 16 14.8 14.8 14 12 9.4 10 8 6 4 2 0 P2 DL3 Target Pivotal Phase 2 14.8 months Population Median overall survival in subjects who P2 DL3 Ta
Slide 26: Achieving Transplant: an Important Clinical Outcome
Achieving Transplant: an Important Clinical Outcome Subjects Who Received or Eligible for HSCT (%) 100 90 20 80 100% 70 Received or 60 Eligible for 50 HSCT 40 80 75 30 In Phase 2 target 55 50 20 population 10 17 0 P2 Overall P2 DL2 (n=6) P2 DL2i (n=4) P2 DL3 (n=12) Target Pivotal (n=22) Phase 2 tria
Slide 27: Improved Survival in Patients Who Achieved Transplant
Improved Survival in Patients Who Achieved Transplant Overall Survival Based on Receiving HSCT (%) All subjects All subjects in P2 DL3 in P2 DL3 received or received or were eligible were eligible for HSCT for HSCT P27
Slide 28: No Impact of Prior Lines of Treatment on Outcome
No Impact of Prior Lines of Treatment on Outcome No Impact of Prior Lines of Treatment on Outcome Overall Survival Based on Receiving HSCT (P2) P28
Slide 29: High ORR in Patients Who Had Prior Inotuzumab
High ORR in Patients Who Had Prior Inotuzumab ORR in Patients with Prior Exposure to Inotuzumab 100 90 Deep 80 15 responses 70 8 60 with prior 50 100 CD22 40 71 30 61 targeted 20 11 therapy 10 11 0 P1 (n (n == 4) 9) P2 (n (n =1 =1 1)3) P2 DL3 (n=5) Target Pivotal Phase 2 Population (n=4) MRD -ve ORR
Slide 30: High CR/CRi Rate in Patients Who Had Prior Inotuzumab
High CR/CRi Rate in Patients Who Had Prior Inotuzumab CR/CRi Rates with Prior Inotuzumab Exposure (%) 70 60 Deep 50 responses 40 with prior 30 60 CD22 20 43 targeted 11 31 10 therapy 11 0 P1 (n=9) P2 (n=13) P2 DL3 (n=7) Target Pivotal Phase 2 population (n=5) MRD-ve CR/CRi MRD+ve CR/CRi P30 Percenta
Slide 31: High ORR in Patients Exposed to Prior Targeted Therapies
High ORR in Patients Exposed to 3 Prior Targeted Therapies: Inotuzumab, Blinatumomab and CD19 CAR-T ORR in Patients with Prior Exposure to 3 Targeted Therapies: Blin, Ino and CD19 CAR-T Deep 100 responses if 90 20 80 received all 3 70 9 60 available 50 100 40 targeted 80 64 30 therapies 20 25 10 0 P
Slide 32: High CR/CRi Rates in Patients Exposed to Prior Targeted Therapies
High CR/CRi Rates in Patients Exposed to 3 Prior Targeted Therapies: Inotuzumab, Blinatumomab and CD19 CAR-T CR/CRi Rate in Patients with Prior Exposure to 3 Targeted Therapies: 80 Blin, Ino and CD19 CAR-T 70 Deep 60 responses if 50 received all 3 available 40 targeted 75 therapies 30 60 20 36 25 10
Slide 33: Low Incidence of Grade ≥3 CRS and ICANS
Low Incidence of Grade ≥ 3 CRS and ICANS CRS and ICANS: DL3 (N=18) CRS and ICANS: Total Population 100 (N=40) 100 90 90 80 5.5 80 70 2.5 70 60 39 60 50 32.5 50 40 40 12 30 30 12 20 39 20 5 37.5 10 10 10 17 7.5 0 0 CRS ICANS CRS ICANS Grade1 Grade 2 Grade 3 Grade1 Grade 2 Grade 3 P33 ICANS: Immune ef
Slide 34: No Current Signal for IEC-HS
No Current Signal for IEC-HS Significant interest in the risk of IEC-HS based on prior CD22 targeting autologous CAR-T No ▪ One case observed evidence of in BALLI-01 IEC-HS CD22 target ▪ Grade 2 HLH Day 5 incidence related ▪ Resolved with Anakinra/Dex effect P34 IEC-HS: Immune Effector Cell–Associat
Slide 35: Lasme-cel Related SAEs
Lasme-cel | Related SAEs* Preferred Term Grade Dose Level DL3 (n=18) ALL (n=40) 3 DL3 1 (5.5) Cytokine release syndrome 2 (5) 2 DL2 Immune effector cell-associated 3 DL3 2 (11.1) 2 (5) neurotoxicity syndrome Platelet count decreased 4 DL2 1 (2.5) Hydrocephalus 3 DL2 1 (2.5) Sepsis 5 DL2 1 (2.5) Graf
Slide 36: Lasme-cel Adverse Events of Special Interest
Lasme-cel | Adverse Events of Special Interest (AESI) Preferred Term Grade Dose Level DL3 (N=18, %) All (N=40, %) Patients with at least 1 AESI 4 (22.2) 5 (12.5) Cytokine release syndrome 3 DL3 (P2) 1 (5.5) 1 (2.5) Immune effector cell-associated 3 DL3 (P2) 2 (11.1) 2 (5) neurotoxicity syndrome Graf
Slide 37: CLLS52 Related Infections: Grade ≥3
CLLS52 Related Infections: Grade ≥ 3 7/35 (20%) of subjects had infection Grade ≥ 3 considered related to alemtuzumab Phase 2 Risk Mitigation: Enhanced Prophylaxis Related to Related to Related to P1 or P2 Dose Level Preferred Term Grade Alemtuzumab Cyclophosphamide Fludarabine P1 DL3 Oral herpes 3
Slide 38: CMV Reactivation: All Subjects
CMV Reactivation: All Subjects Grade Related to Related to Related to Related to Dose Level P1 or P2 Preferred Term Value UCART Alemtuzumab Cyclophosphamide Fludarabine DL2 P1 Cytomegalovirus infection 2 No YES YES YES Cytomegalovirus infection DL2I P1 2 No NO NO NO reactivation DL2 P2 Cytomegalovir
Slide 39: Data Suggest Alemtuzumab Is Key to Achieving Response
Data Suggest Alemtuzumab Is Key to Achieving Response Patients Who Achieved MRD- Negative Status 60 55% 50 40 Deeper 31% Responses With P2 30 Alemtuzumab as P Part of 20 2 Lymphodepletion P1 P 10 1 0% 0 n=22 n n= =5 5 n= n= 113 3 n=22 FCA FC FCA FC FCA FCA P39 FC: Fludarabine and cyclophosphamide ;
Slide 40: BALLI-01 Transition to Pivotal Phase 2
R&D Day BALLI-01 Transition to Pivotal Phase 2 DRAFT
Slide 41: Clear Registration Path for Lasme-Cel in r/r-ALL
Clear Registration Path for Lasme-Cel in r/r-ALL P41
Slide 42: Phase 2 Pivotal Phase Study Design
Phase 2 Pivotal Phase 2 Study Design: Pivotal Phase 2 Interim analysis 2: Primary analysis Interim analysis 1: Overall 50% pivotal Cohort for BLA Dose Optimization Survival Primary Endpoint: CR / CRi, evaluated within 3 months (from Day 28 to Day 84) Age 12-50 years P42
Slide 43: Age Distribution of ALL Target Phase 2 Population
Age Distribution of ALL 8 Target Phase 2 population (Including Pediatric Plan) 7 Potential future target population 6 5 Current plan includes 4 patients 0-50 years old: 3 >70% of total patients 2 1 0 <1 1-4 5-9 10-14 15-19 20-29 30-39 40-49 50-59 60-69 70-79 80+ Age P43 Incidence per 100,000
Slide 44: Recruitment Driven by Planned Study Sites
Recruitment Driven by 75 Planned Study Sites 75 Study centers planned in North America and Europe P44
Slide 45: Clear Registration Path to BLA Submission Targeted For 2028
Clear Registration Path to BLA Submission Targeted For 2028: Key Anticipated Milestones Multiple Catalysts to 2H 2028 P45 BLA: Biologics licence application
Slide 46: Lasme-cel Commercial Opportunity
R&D Day Lasme-cel Commercial Opportunity DRAFT
Slide 47: Lasme-cel is a Highly Differentiated Off-the-shelf CAR-T
Lasme-cel is a Highly Differentiated Off-the-shelf CAR-T Lasme-cel Product Overview and Differentiation Potential first-in-class CD22 CAR-T, providing a potent alternative to CD22 CAR CD19-targeting agents Off-the-shelf therapy enables immediate treatment initiation, Allogeneic Therapy significantly
Slide 48: Lasme-cel Can Fill Whitespace In the B-ALL Treatment Paradigm
Lasme-cel Can Fill Whitespace In the B-ALL Treatment Paradigm Select FDA-Approved Therapies in B-ALL Target CD19 CD22 ADC TCE Auto CAR-T Lasme-cel Allo CAR-T Lasme-cel is positioned to be the first CD22 allogeneic CAR-T therapy to market Additional treatments not shown include chemotherapy and TKIs
Slide 49: Chemo and CD19-directed Therapies are Mainstays of B-ALL Treatment
Chemo and CD19-directed Therapies are Mainstays of B-ALL Treatment ALL Treatment Paradigm 1 Induction: Chemo (± TKI ) Initial treatment with chemo ± TKI, with Blincyto Frontline (CD19 TCE) consolidation increasingly used in ± Chemo ± TKI Consolidation: Blincyto 1L following 2024 label expansion 1 Pa
Slide 50: Chemo and CD19-directed Therapies are Mainstays of B-ALL Treatment
Chemo and CD19-directed Therapies are Mainstays of B-ALL Treatment ALL Treatment Paradigm 1 Induction: Chemo (± TKI ) Initial treatment with chemo ± TKI, with Blincyto Frontline (CD19 TCE) consolidation increasingly used in ± Chemo ± TKI Consolidation: Blincyto 1L following 2024 label expansion Ofte
Slide 51: Chemo and CD19-directed Therapies are Mainstays of B-ALL Treatment
Chemo and CD19-directed Therapies are Mainstays of B-ALL Treatment ALL Treatment Paradigm 1 Induction: Chemo (± TKI ) Initial treatment with chemo ± TKI, with Blincyto Frontline (CD19 TCE) consolidation increasingly used in ± Chemo ± TKI Consolidation: Blincyto 1L following 2024 label expansion Ofte
Slide 52: Chemo and CD19-directed Therapies are Mainstays of B-ALL Treatment
Chemo and CD19-directed Therapies are Mainstays of B-ALL Treatment ALL Treatment Paradigm 1 Induction: Chemo (± TKI ) Initial treatment with chemo ± TKI, with Blincyto Frontline (CD19 TCE) consolidation increasingly used in ± Chemo ± TKI Consolidation: Blincyto 1L following 2024 label expansion Ofte
Slide 53: Lasme-cel Potential to Reach Up To ~1.9K Addressable 3L+ Patients
Lasme-cel Has the Potential to Reach Up To ~1.9 K Addressable 3L+ Patients U.S. and EU4+UK 2035E Lasme-cel Addressable Population Incident 1L Treated B-ALL Population (2035E) ~9.2 K Patients (~5.1 K U.S. + ~4.1 K EU4+UK) Note: Values may not multiply exactly due to rounding. Source: Joshi. Clin Ly
Slide 54: Lasme-cel Potential to Reach Up To ~1.9K Addressable 3L+ Patients
Lasme-cel Has the Potential to Reach Up To ~1.9 K Addressable 3L+ Patients U.S. and EU4+UK 2035E Lasme-cel Addressable Population Incident 1L Treated B-ALL Population (2035E) ~9.2 K Patients (~5.1 K U.S. + ~4.1 K EU4+UK) Of the ~9.2 K expected B-ALL patients, ~45% are expected to progress to 2L, ~45
Slide 55: Lasme-cel Potential to Reach Up To ~1.9K Addressable 3L+ Patients
Lasme-cel Has the Potential to Reach Up To ~1.9 K Addressable 3L+ Patients U.S. and EU4+UK 2035E Lasme-cel Addressable Population Incident 1L Treated B-ALL Population (2035E) ~9.2 K Patients (~5.1 K U.S. + ~4.1 K EU4+UK) Of the ~9.2 K expected B-ALL patients, ~45% are expected to progress to 2L, ~45
Slide 56: Lasme-cel Potential to Reach Up To ~1.9K Addressable 3L+ Patients
Lasme-cel Has the Potential to Reach Up To ~1.9 K Addressable 3L+ Patients U.S. and EU4+UK 2035E Lasme-cel Addressable Population Incident 1L Treated B-ALL Population (2035E) ~9.2 K Patients (~5.1 K U.S. + ~4.1 K EU4+UK) Of the ~9.2 K expected B-ALL patients, ~45% are expected to progress to 2L, ~45
Slide 57: Lasme-cel Has the Potential To Capture a Majority of the 3L+ Market
Lasme-cel Has the Potential To Capture a Majority of the 3L+ Market Value Proposition of 3L+ Treatment Options “MRD negativity is very Lasme-cel encouraging compared to what we have in third Ç Alternative target to CD19Ç Off-the shelf availability line.” – ALL Key Opinion Leader Ç One-time dosingÇ D
Slide 58: Lasme-cel Has High Pricing Potential Across the EU4 + UK and U.S.
Lasme-cel Has High Pricing Potential Across the EU4 + UK and U.S. Lasme-cel Ilustrative List Price, If Approved 500 Tecartus 400 Lasme-cel 300 Kymriah 200 2025 Avg: ~$365 K 100 0 2020 2025 2030 2035 • Lasme-cel illustrative anchor price triangulated from 2025 averaged EU4 + UK CAR-T price range of $
Slide 59: Lasme-cel Has High Pricing Potential Across the EU4 + UK and U.S.
Lasme-cel Has High Pricing Potential Across the EU4 + UK and U.S. Lasme-cel Ilustrative List Price, If Approved 500 1,000 Kymriah Tecartus +5% 400 800 Aucatzyl Lasme-cel 300 600 Lasme-cel Kymriah Tecartus 200 400 2025 Avg: ~$365 K 100 200 2025 Avg: ~$515 K 0 0 2020 2025 2030 2035 2020 2025 2030 2035
Slide 60: Lasme-cel Could Achieve Up To ~$700M in Peak Gross Sales
Lasme-cel Could Achieve Up To ~$700 M in Peak Gross Sales (U.S., EU4, UK) Assumption Source / Rationale Addressable Patients (#) ~1.1 K ~840 Represents expected 3L CAR-T eligible patients in 2035 x x • Triangulated using physician-reported preferences and average market share of Preference Share (%)
Slide 61: Peak Sales Could Increase to Up To ~$1.3B with Label Expansion
Peak Sales Could Increase to Up To ~$1.3 B with Label Expansion ILLUSTRATIVE Allo CAR-T Eligible Patients Patient Segment Peak Sales 2035E 3L+ (Potential First Approval) ~$700 M Large opportunity in the initial lasme-cel 1 Current CAR-T U.S. ~450 indication 2 EU ~350 Treated Patients + Expansion to
Slide 62: Lasme-cel Can Drive Meaningful Growth of the CAR-T Market In B-ALL
Lasme-cel Can Drive Meaningful Growth of the CAR-T Market In B-ALL First-in-class Immunotherapy Beyond CD19 Lasme-cel Deep Responses with High CR Rates Opportunity and Impressive MRD Negativity Robust Peak Sales Potential (Up To ~$700 M) With Highly Attractive Margins CR: Complete Remission; MRD: Mi
Slide 63: Clear Registration Path to BLA Submission Targeted For 2028
Clear Registration Path to BLA Submission Targeted For 2028: Key Anticipated Milestones Multiple Catalysts to 2H 2028 P63
Slide 64: Cellectis Strategic Roadmap
Cellectis Strategic Roadmap Lasme-cel Potential BLA Filing in r/r B-ALL (2028) Eti-cel Potential EoP1 in r/r NHL (2026) Preclinical PoC for In Vivo Gene Therapy (2026) P64 EoP1: End-of-Phase 1 ; PoC: Proof-of-concept
Slide 65: Thank You
Thank You Reach us at: investors@cellectis.com Cellectis Raleigh Cellectis New York Cellectis Paris 2500 Sumner Boulevard 8, rue de la Croix Jarry 75013 430 East 29th Street Raleigh, NC, 27616 – USA Paris – France New York, NY, 10016 – USA Cellectis®, TALEN® and our corporate logos are registered tr